Address Hotels and Resorts Announces the Opening of Address Jabal Omar Makkah Unveiling a Spiritual Haven in the Heart of Makkah
Address Hotels and Resorts is thrilled to announce the opening of its latest architectural and hospitality masterpiece, Address Jabal Omar Makkah, in the holy city of Makkah, Saudi Arabia. Nestled in the iconic Jabal Omar development, this landmark property offers a truly unforgettable experience for pilgrims and travellers alike.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230711493267/en/
Panoramic Kaaba view from Address Jabal Omar Makkah (Photo: AETOSWire)
The largest hotel within the Address Hotels and Resorts portfolio, Address Jabal Omar Makkah boasts an impressive 1,484 rooms and suites. With its striking architectural design, a seamless fusion of ancient Arabian charm and contemporary opulence, the hotel is the tallest building in Jabal Omar and is a breathtaking sight.
One standout feature of Address Jabal Omar Makkah is its proximity to the sacred Holy Kaaba and Al Masjid Al Haram, along with the Makkah Museum, Masjid Al Jinn, Jannat al-Mu'alla Cemetery, and the iconic Abraj Al Bait Towers. Designed by the world-renowned architects Foster & Partners, the towers of Address Jabal Omar Makkah span over 5,000 sqm and the development includes a commercial area featuring a diverse range of shops, showcasing local, regional, and international brands.
Address Jabal Omar Makkah offers a range of exquisitely designed accommodations to suit every traveller’s needs. From luxurious Deluxe Rooms, which provide splendid views of the Holy Kaaba or the Holy City, to indulgent Suites and the magnificent three-bedroom Presidential Suite and four-bedroom Penthouse, guests can immerse themselves in comfort and elegance.
With four restaurants, two lobby lounges, and two club lounges, guests can also savour a wide range of delectable cuisines. The hotel's signature dining venue offers traditional Hejazi cuisine and other Saudi Arabian specialties, where live cooking stations showcase international flavours alongside time-honoured delicacies.
The spa and wellness offerings, including the first-ever Foot Spa by Address Hotels and Resorts, at the hotel are designed to provide guests with a truly holistic experience. With a complimentary Fitness Centre, equipped with the latest Technogym equipment on hand as well, guests can maintain their well-being during their stay.
Address Jabal Omar Makkah is also a premier destination for conferences and events. Whatever the occasion, the hotel’s unparalleled settings and services help create cherished moments. The property's multifunctional meeting spaces are designed to cater to events of any scale. The hotel's creative chefs curate menus tailored to individual preferences, ensuring a flawless and memorable event.
Mark Kirby, Head of Emaar Hospitality, said, “We are delighted to announce the opening of Address Jabal Omar Makkah. Its prime location makes it the preferred choice for those seeking to deepen their spiritual connection. With spacious rooms and suites, multiple dining options, and state-of-the-art prayer facilities, the hotel offers all the amenities necessary for a meaningful and unforgettable pilgrimage experience. Whether guests are here for Hajj, Umrah, or to enhance their spiritual connection, Address Jabal Omar Makkah Hotel is the optimal starting point for their journey.”
The hotel is proud to be a part of Saudi Arabia's Vision 2030, which aims to transform the country's tourism landscape.
To reserve with a 15% discount, click the link, visit our website, or email stayatmakkah@addresshotels.com or call +966-0125531444.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230711493267/en/
Contact information
Mohammad Jamil
Mohammad.j@addresshotels.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom